Cargando…

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) is the most commonly mutated gene found in acute myeloid leukemia (AML) patients and its activating mutations have been proven to be a negative prognostic marker for clinical outcome. Pacritinib (SB1518) is a tyrosine kinase inhibitor (TKI) with equipotent activity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hart, S, Goh, K C, Novotny-Diermayr, V, Tan, Y C, Madan, B, Amalini, C, Ong, L C, Kheng, B, Cheong, A, Zhou, J, Chng, W J, Wood, J M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256753/ https://www.ncbi.nlm.nih.gov/pubmed/22829080 http://dx.doi.org/10.1038/bcj.2011.43

Ejemplares similares

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
por: Novotny-Diermayr, V, et al.
Publicado: (2012)

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
por: Verstovsek, Srdan, et al.
Publicado: (2016)

Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3
por: Ghezzi, Chiara, et al.
Publicado: (2023)

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

Emerging treatment options for myelofibrosis: focus on pacritinib
por: Chow, Vivian, et al.
Publicado: (2016)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
por: Vannucchi, A., et al.
Publicado: (2022)

Profile of pacritinib and its potential in the treatment of hematologic disorders
por: Hatzimichael, Eleftheria, et al.
Publicado: (2014)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Correction to Lancet Oncol 2021; 22: 1518–29
Publicado: (2022)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL
por: Zamora, Ernesto José Cuenca, et al.
Publicado: (2023)

P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA
por: Viprakasit, V., et al.
Publicado: (2022)

1518. The Microbiology of Osteoarticular Infections in Patients with Sickle Hemoglobinopathies at Texas Children’s Hospital, 2011–2018
por: Ikeda, Saki, et al.
Publicado: (2019)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
por: Torres, Sandra, et al.
Publicado: (2023)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
por: Singer, Jack W, et al.
Publicado: (2016)

Pacritinib abrogates the lupus phenotype in ABIN1[D485N] mice
por: Petrova, Tsvetana, et al.
Publicado: (2023)

Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib
por: Yacoub, Abdulraheem, et al.
Publicado: (2023)

Tres siglos de pensamiento económico, 1518-1817/Jesús Silva Herzog
por: Silva Herzog, Jesús, 1892-1985
Publicado: (1950)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
por: Harrison, Claire, et al.
Publicado: (2023)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS
por: Gagelmann, Nico, et al.
Publicado: (2023)

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
por: Razak, A R A, et al.
Publicado: (2011)

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies
por: Zhou, Jianbiao, et al.
Publicado: (2018)

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
por: Gansmo, Liv B., et al.
Publicado: (2017)

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis
por: Al-Fayoumi, Suliman, et al.
Publicado: (2018)

Two sb or not two sb?
por: Kado, M, et al.
Publicado: (2000)

1518 Hand Hygiene for Patients: an Initiative to Study and Promote Hand Hygiene Practice for Hospitalized Patients
por: Pokrywka, Marian, et al.
Publicado: (2014)

Acylated Aminooligosaccharides with Inhibitory Effects against α-Amylase from Streptomyces sp. HO1518
por: Liu, Hai-Li, et al.
Publicado: (2018)

P1518: INFECTIONS FOLLOWING BISPECIFIC ANTIBODIES IN MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Reynolds, Gemma, et al.
Publicado: (2023)

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate
por: Gansmo, Liv B., et al.
Publicado: (2016)

Fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 reduces bacterial translocation in rats treated with carbon tetrachloride
por: Sánchez, Elisabet, et al.
Publicado: (2017)

Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women
por: Clavel, C, et al.
Publicado: (1999)

Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

On the decay of 110Sb, 111Sb, 112Sb, 113Sb and 114Sb
por: Sunier, J W, et al.
Publicado: (1970)

The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model
por: Jensen, Katharine Victoria, et al.
Publicado: (2017)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
por: Masarova, Lucia, et al.
Publicado: (2023)

Nuño de Guzmán y la provincia de Pánuco en Nueva España, 1518-1533
por: Chipman, Donald E.
Publicado: (2007)

MDM2 promoter del1518 polymorphism and cancer risk: evidence from 22,931 subjects
por: Hua, Wenfeng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5oph7t9sillf228nsce5m0aunk